Bio View (XTAE:BIOV) EBIT : ₪1.75 Mil (TTM As of Jun. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Bio View EBIT?

Bio View's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was ₪2.59 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was ₪1.75 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bio View's annualized ROC % for the quarter that ended in Jun. 2024 was 8.44%. Bio View's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 59.81%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bio View's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 5.45%.

Bio View EBIT Historical Data

The historical data trend for Bio View's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio View EBIT Chart

Bio View Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

3.43

1.19

2.92

1.11

Bio View Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT	Get a 7-Day Free Trial															0.05	1.07	1.95	-0.84	2.59

Competitive Comparison of Bio View's EBIT

For the Medical Devices subindustry, Bio View's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio View's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio View's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bio View's EV-to-EBIT falls into.

Bio View EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₪1.75 Mil.

Bio View (XTAE:BIOV) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bio View's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	2.154 * ( 1 - 17.67% )	/	( (22.184	+	19.816)	/ 2 )
=	1.7733882	/	21
=	8.44 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	41.955	-	2.657	-	( 17.114	-	max(0, 11.909	-	31.932	+	17.114	))
=	22.184

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	42.678	-	6.064	-	( 16.798	-	max(0, 11.7	-	33.778	+	16.798	))
=	19.816

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Bio View's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	5.178	/	( ( (4.122 + max(3.846, 0))	+	(3.325 + max(6.022, 0)) )	/	2 )
=	5.178	/	( ( 7.968	+	9.347 )	/	2 )
=	5.178	/	8.6575
=	59.81 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(7.408	+	6.306	+	0.486)	-	(2.657	+	0	+	7.697)
=	3.846

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(7.609	+	8.392	+	7.105427357601E-15)	-	(6.064	+	0	+	3.915)
=	6.022

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bio View's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	1.748	/	32.093
	=	5.45 %

Bio View EBIT Related Terms

Thank you for viewing the detailed overview of Bio View's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio View Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio View Ltd (XTAE:BIOV) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Pekeris Street, Rehovot, ISR, 7670203

Website

http://www.bioview.co.il

Bio View Ltd is an Israel based company engaged in the research, development, manufacture, marketing, and sale of computerized systems for identification of rate cells and test for detection of cancer. It manufactures and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. Geographically, the group has its business presence in Israel, USA, and other countries, of which majority of the revenue is derived from the USA.

Bio View Headlines

No Headlines